Srinivas Akkaraju bought $4.0M of SYRS
director at Syros Pharmaceuticals, Inc.. 904,977 shares at an average of $4.42, traded Dec 21, 2023, filed Dec 26, 2023.
Score components
- +15RoleDirector
- +25Trade size$4.0M at market
- +10Relative to holdingsHoldings up 103%
- 0Price contextMid range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- +10Track recordMedian 6-month excess return +66% over 14 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.6%, 3m -10.7%, 6m -17.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-059693, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 21, 2023 | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +904,977 | $4.42 | $4.0M | 1,786,427 | Dec 26, 2023 |
Related signals
Other insiders at Syros Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Syros Pharmaceuticals, Inc. | Nancy A Simonian President & CEO | $10k 37,070 shares | -90% | |
| 56Moderate | Syros Pharmaceuticals, Inc. | Nancy A Simonian President & CEO | $36k 134,713 shares | -77% | |
| 65Notable | Syros Pharmaceuticals, Inc. | Conley Chee President & CEO | $27k 134,797 shares | -100% | |
| 62Notable | Syros Pharmaceuticals, Inc. | Jason Haas Chief Financial Officer | $29k 137,803 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | Gerald E Quirk Chief Legal & Compliance Offic | $10k 46,657 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | David Roth Chief Medical Officer | $2,382 12,099 shares | -100% | |
| 50Moderate | Syros Pharmaceuticals, Inc. | Kristin Stephens Chief Development Officer | $7,949 36,133 shares | -100% | |
| 72Notable | Syros Pharmaceuticals, Inc. | Conley Chee President & CEO | $161k 100,000 shares | +444% | |
| 69Notable | Syros Pharmaceuticals, Inc. | Jason Haas Chief Financial Officer | $161k 100,000 shares | +407% | |
| 27Weak | Syros Pharmaceuticals, Inc. | Richard A Young director | $178k 34,837 shares | -81% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.